Key Insights

Highlights

Success Rate

85% trial completion

Published Results

296 trials with published results (27%)

Research Maturity

745 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

12.2%

136 terminated out of 1115 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

18%

196 trials in Phase 3/4

Results Transparency

40%

296 of 745 completed with results

Key Signals

296 with results85% success136 terminated

Data Visualizations

Phase Distribution

930Total
Not Applicable (215)
Early P 1 (10)
P 1 (229)
P 2 (280)
P 3 (132)
P 4 (64)

Trial Status

Completed745
Terminated136
Unknown108
Recruiting58
Withdrawn28
Active Not Recruiting17

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 745 completed trials

Clinical Trials (1115)

Showing 20 of 20 trials
NCT07214727Phase 1RecruitingPrimary

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

NCT07170150Phase 3RecruitingPrimary

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT06976203Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT00412048Not ApplicableWithdrawnPrimary

Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

NCT07177352Phase 3RecruitingPrimary

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07169578Phase 3RecruitingPrimary

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07234942Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

NCT02520232Not ApplicableCompletedPrimary

Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition

NCT05837819Not ApplicableCompletedPrimary

Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2

NCT05462106Phase 1Recruiting

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT06976216Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06548191Phase 1Recruiting

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

NCT03269149Not ApplicableCompletedPrimary

Tango for Alzheimer's Disease Patients' Caregivers

NCT06546995Phase 1CompletedPrimary

Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

NCT05463731Phase 3CompletedPrimary

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT07553338Phase 2Recruiting

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

NCT07599670Phase 1Not Yet RecruitingPrimary

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenous ABBV-1758 Moves Through the Body of Adult Participants With Alzheimer's Disease

NCT02467413Phase 2WithdrawnPrimary

BAC in Patient With Alzheimer's Disease or Vascular Dementia

NCT00149175CompletedPrimary

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

NCT06402838Phase 2Active Not RecruitingPrimary

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

Scroll to load more

Research Network

Activity Timeline